ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Whole-brain radiotherapy with simultaneous integrated boost in treatment of patients with brain metastases: a systematic review and meta-analysis.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWhole-brain radiotherapy (WBRT) remains the standard treatment for patients with multiple brain metastases (BM), who are not candidates for focal radiotherapy or surgery. A novel approach, WBRT with simultaneous integrated boost (WBRT-SIB), has shown promising results in improving intracranial control and survival compared with WBRT alone. However, no meta-analysis has comprehensively compared those strategies. METHODS/PATIENTS: A systematic review and meta-analysis was performed in accordance with the PRISMA guidelines. Studies indexed up to September 1, 2025, were identified in PubMed, Embase, and Web of Science. Pooled hazard ratios (HRs) were calculated for overall survival (OS), intracranial progression-free survival (iPFS), and intracranial local PFS (iLPFS); odds ratios (ORs) were used for treatment-related adverse events (TRAEs).
resultsThirty studies involving 2,033 patients were analyzed. WBRT-SIB significantly improved OS (HR = 0.7, 95%CI 0.5-0.96, p = 0.03), iPFS (HR = 0.67, 95%CI 0.47-0.96, p = 0.03), and iLPFS (HR = 0.55, 95%CI 0.4-0.79, p < 0.01) compared with WBRT alone. The benefit was mostly driven by patients with small-cell lung cancer (SCLC) (HR = 0.54, 95%CI 0.31-0.92, p = 0.025), while no significant effect was observed for other tumor types. Median OS after WBRT-SIB was 16.78 months, iPFS was 13.07 months, and the objective response rate was 69.5%. WBRT-SIB did not increase the risk of TRAEs, and the incidence of radiation necrosis was 5.05% (95%CI 1.19%-10.77%).
conclusionWBRT-SIB improves intracranial control and may improve overall survival compared with WBRT alone, mostly in patients with SCLC, achieving high response rates with acceptable safety. These results support further investigation of WBRT-SIB for patients with BM who are not candidates for stereotactic radiosurgery.
Indexed as
Identifiers
42171981What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.